Pfizer Inc (PFE) - News Archive

In a defining moment for the hemophilia B community and the broader domain of genetic medicine, the U.S. Food and Drug Administration (FDA) has recently sanctioned Pfizer’s BEQVEZ (fidanacogene elaparvovec-dzkt). Showca...

The European Commission (EC) has recently granted marketing authorization to Pfizer Inc. for EMBLAVEO (aztreonam-avibactam), marking a significant development in the treatment of adult patients with complicated intra-ab...

Pfizer Inc. has recently received marketing authorization from the European Commission (EC) for its 20-valent pneumococcal conjugate vaccine, known as PREVENAR 20. This vaccine aims to actively immunize infants, childre...

Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract disease (LRTD) in older adults, leading to severe health complications and hospitalizations. Pfizer Inc. has recently announced positiv...

In an encouraging development for patients with moderately to severely active ulcerative colitis (UC), Pfizer Inc. has announced that its drug VELSIPITY (etrasimod) has been granted marketing authorization by the Europe...

In a significant development for the field of oncology, Carrick Therapeutics has announced the dosing of the first patient in its Phase 1b/2 clinical trial. The trial aims to evaluate the efficacy and safety of samuraci...

Arvinas, in collaboration with Pfizer, has reached a significant milestone in cancer research as their investigational drug, vepdegestrant (ARV-471), receives Fast Track designation from the U.S. Food and Drug Administr...

European Medicines Agency Validates Application for PADCEV and KEYTRUDA Combination Therapy for Advanced Bladder Cancer TreatmentOn January 26, Pfizer Inc. and Astellas Pharma Inc. announced that the European Medicines...

Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) recently declared a significant stride in the pharma realm with their breakthrough drug TIVDAK (tisotumab vedotin-tftv), earmarked for the treatment of recurrent or...

In a major breakthrough for the treatment of metastatic castration-resistant prostate cancer (mCRPC), Pfizer Inc. has announced that the European Commission (EC) has granted approval for its oral poly ADP-ribose polymer...

Pfizer Inc., a renowned pharmaceutical company, recently announced that it will be hosting a conference call on January 30, 2024, to discuss its Fourth Quarter and Full Year 2023 Performance Report. The call aims to pro...

In a breakthrough development for the medical community, Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503) have announced that their combination of PADCEV (enfortumab vedotin-ejfv) and KEYTRUDA (pembrolizumab)...

NEW YORK - Pfizer Inc. (NYSE: PFE) continues to prioritize its shareholders as it declares an increase in the quarterly cash dividend on the company s common stock to $0.42 for the first quarter of 2024. This marks the...

In a recent financial forecast, Pfizer Inc. (NYSE: PFE) has shared its expectations for the 2024 fiscal year, now charting its financial future amidst an evolving economic stage marred by uncertain industrial dynamics....

:Pfizer Inc. has received regulatory acceptance for its Biologics License Application (BLA) for marstacimab, an anti-tissue factor pathway inhibitor (anti-TFPI) candidate. The U.S. Food and Drug Administration (FDA) has...

In a recent press release, pharmaceutical giant Pfizer Inc. shared promising topline data from their Phase 2b clinical trial investigating the oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipr...

Arvinas, Inc. and Pfizer Inc. have recently shared exciting updates regarding their joint efforts to develop vepdegestrant (ARV-471), a groundbreaking oral drug that targets estrogen receptor (ER) degradation. The updat...

In a significant step towards protecting adolescents and young adults against the most common serogroups causing meningococcal disease, the U.S. Food and Drug Administration (FDA) has granted approval to PENBRAYA, Pfize...

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 GuidanceIn a recent announcement, Pfizer Inc. disclosed that it has made amendments to its supply agreement with the U.S. government for...

Pfizer Inc. (NYSE: PFE) has recently announced its declaration of a fourth-quarter 2023 dividend on the company s common stock. The dividend of $0.41 per share will be paid out on December 4, 2023, to holders of the Com...